Transmedics Group Inc’s recent filing unveils that its insider Ranganath Anil P. unloaded Company’s shares for reported $95903.0 on Jun 09 ’25. In the deal valued at $139.80 per share,686 shares were sold. As a result of this transaction, Ranganath Anil P. now holds 13,955 shares worth roughly $1.98 million.
Then, Basile Edward M sold 5,000 shares, generating $632,250 in total proceeds. Upon selling the shares at $126.45, the Director now owns 2,866 shares.
Before that, EDWARD BASILE bought 5,000 shares. Transmedics Group Inc shares valued at $632,250 were divested by the Director at a price of $126.45 per share.
JP Morgan downgraded its Transmedics Group Inc [TMDX] rating to a Neutral from a an Overweight in a research note published on December 17, 2024; the price target was decreased to $75 from $116. A number of analysts have revised their coverage, including Needham’s analysts, who decreased its forecast for the stock in late November from “a Buy” to “a Hold”. Oppenheimer also remained covering TMDX and reiterated its “an Outperform” recommendation on October 29, 2024. Needham maintained its rating on October 29, 2024. It rated TMDX as “a Buy”.
Price Performance Review of TMDX
On Monday, Transmedics Group Inc [NASDAQ:TMDX] saw its stock fall -0.64% to $141.96. Over the last five days, the stock has gained 1.84%. Transmedics Group Inc shares have risen nearly 127.68% since the year began. Nevertheless, the stocks have risen 0.06% over the past one year. While a 52-week high of $177.37 was reached on 06/16/25, a 52-week low of $55.00 was recorded on 01/21/25.
Levels Of Support And Resistance For TMDX Stock
The 24-hour chart illustrates a support level at 139.18, which if violated will result in even more drops to 136.40. On the upside, there is a resistance level at 145.12. A further resistance level may holdings at 148.28.
The most recent change occurred on September 24, 2024 when Robert W. Baird began covering the stock and recommended ‘”an Outperform”‘ rating along with a $200 price target.
